Aprepitant - A novel NK1 -receptor antagonist

Expert Opinion on Pharmacotherapy

Volumn 4, Issue 12, 2003, Pages 2279-2296

  Patel, Lisa ^a   Lindley, Celeste ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Aprepitant; CINV; NK1 receptor antagonists; Subtance P antagonists

Indexed keywords

2 [1 [3,5 BIS(TRIFLUOROMETHYL)PHENYL]ETHOXY] 3 (4 FLUOROPHENYL) 4 (3 OXO 1 PHOSPHORYL 1,2,4 TRIAZOL 5 YLMETHYL)MORPHOLINE; APREPITANT; CISPLATIN; COPPER SULFATE; CYCLOPHOSPHAMIDE; CYTOCHROME P450 3A4; CYTOTOXIC AGENT; DEXAMETHASONE; DILTIAZEM; ERYTHROMYCIN; FLUOXETINE; GRANISETRON; KETOCONAZOLE; METHYLPREDNISOLONE; METOCLOPRAMIDE; MIDAZOLAM; MORPHINE; NEUROKININ 1 RECEPTOR; NEUROKININ 1 RECEPTOR ANTAGONIST; ONDANSETRON; ORAL CONTRACEPTIVE AGENT; PAROXETINE; PLACEBO; RIFAMPICIN; SEROTONIN 3 ANTAGONIST; SUBSTANCE P; SUBSTANCE P ANTAGONIST; UNCLASSIFIED DRUG; UNINDEXED DRUG; WARFARIN; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; MORPHOLINE DERIVATIVE;

ABDOMINAL PAIN; ACUTE DISEASE; ANOREXIA; ANTIEMETIC ACTIVITY; ANXIETY; ANXIETY DISORDER; AREA UNDER THE CURVE; ASTHENIA; CANCER; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONSTIPATION; COUGHING; DEHYDRATION; DEPRESSION; DIARRHEA; DISEASE CONTROL; DOSE RESPONSE; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLASSIFICATION; DRUG EFFICACY; DRUG FATALITY; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; FATIGUE; FEBRILE NEUTROPENIA; FLUSHING; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL TOXICITY; HEADACHE; HICCUP; HUMAN; IC 50; INFECTION; INFLAMMATION; LEUKOPENIA; LIVER TOXICITY; MENSTRUATION DISORDER; NAUSEA; NEUTROPENIA; NONHUMAN; PAIN; PHARMACODYNAMICS; RESPIRATORY FAILURE; REVIEW; SIDE EFFECT; SOMNOLENCE; STEVENS JOHNSON SYNDROME; TREATMENT INDICATION; VERTIGO; DRUG ANTAGONISM; DRUG INTERACTION; VOMITING;

ANTIEMETICS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; DRUG INTERACTIONS; HUMANS; MORPHOLINES; NAUSEA; RECEPTORS, NEUROKININ-1; VOMITING;

EID: 85047690901     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.4.12.2279     Document Type: Review

References (49)

1. BOER-DENNERT M, WIT R, SCHMITZ PI et al.: Patient perceptions of the side-effects of chemotherapy: the influence of 5-HT3 antagonists. Br. J. Cancer (1997) 76(8):1055-1061.
2. GRIFFIN AM, BUTOW PN, COATES AS et al.: On the receiving end V: patient perceptions of the side effects of cancer chemotherapy in 1993. Ann. Oncol. (1996) 7:189-195.
3. PASSIK SD, KIRSH KL, ROSENFELD B, MCDONALD MV, THEOBALD DE: The changeable nature of patients' fears regarding chemotherapy: implications for palliative care. J. Pain Symptom Mange. (2001) 21(2):113-120.
4. OSOBA D, ZEE B, WARR D, KAIZER L, LATREILLE J, PATER J: Quality of life studies in chemotherapy-induced emesis. Oncology (Huntingt) (1996) 53(Suppl. 1):92-95.
5. LINDLEY CM, HIRSCH JD, O'NEILL CV, TRANSAU MC, GILBERT CS, OSTERHAUS JT: Quality of life consequences of chemotherapy-induced emesis. Qual. Life Res. (1992) 1:331-340.
6. GRALLA RJ, OSABA D, KRIS MC et al.: Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. J. Clin. Oncol. (1999) 17(9):2971-2994.
7. HESKETH P, VAN BELLE S, AAPRO M et al.: Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists. Eur. J. Cancer (2003) 39:1074-1080.
8. 3 receptor antagonists. Support. Care Cancer (1994) 2:286-292.
9. Antiemetic Subcommittee of the Multinational Association of Supportive Care Cancer (MASCC): Prevention of chemotherapy- and radiotherapy-induced emesis: results of the Perugia consensus conference. Ann. Oncol. (1998) 9:811-819.
10. 1 receptor antagonist GR203040. Br. J. Pharmacol. (1995) 116:3158-3163.
11. 1) antagonists. Trends Pharmacol. Sci. (1999) 20:485-490.
12. ICHINOSE M, MIURA M, YAMAUCHI H et al.: A neurokinin 1-receptor antagonist improves exercise-induced airway narrowing in asthmatic patients. Am. J. Repir. Crit. Care Med. (1996) 153(3):936-941.
13. URBAN LA, FOX AJ: NK1 receptor antagonists - are they really without effect in the pain clinic? Trends Pharmacol. Sci. (2000) 21:462-464.
14. HILL R: NK1 (substance P) receptor antagonists - why are they not analgesic in humans? Trends Pharmacol. Sci. (2000) 21:244-246.
15. BEATTIE DT, CONNOR HE, HAGAN RM: Recent developments in tachykinin NK1 receptor antagonists: prospects for the treatment of migraine headache. Can. J. Physiol. Pharmacol. (1995) 73(7):871-877.
16. KRAMER MS, CUTLER N, FEIGHNER J et al.: Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science (1998) 281:1640-1645.
17. Merck & Co., Inc.: Emend® (aprepitant) prescribing information. Merck & Co., Inc. Whitehouse Station, NJ, USA (2003).
18. 1) antagonists in depression. J. Clin. Psychiatr. (2002) 63(Supp. 11):25-29.
19. GENTSCH C, CUTLER M, VASSOUT A, VEENSTRA S, BRUGGER F: Anxiolytic effect of NKP608, a NK1-receptor antagonist, in the social investigation test in gerbils. Behav. Brain Res. (2002) 133(2):363-368.
20. KOVAC AL: Prevention and treatment of postoperative nausea and vomiting. Drugs (2000) 59(2):213-243.
21. ANDREWS PL, NAYLOR RJ, JOSS RA: Neuropharmacology of emesis and its relevance to anti-emetic therapy. Support. Care Cancer (1998) 6:197-203.
22. VON EULER US, GADDUM JH: An unidentified depressor substance in certain tissue extracts. J. Physiol. (1931) 72:74-87.
23. 1 receptor. J. Clin. Psychiatry (2002) 63(Suppl. 11):6-10.
24. HARRISON S, GEPPETTI P: Substance P. Int. J. Biochem. Cell Biol. (2001) 33:555-576.
25. OTSUKA M, KONISHI S.: Neurotransmitter functions of mammalian tachykinins. Physiol. Rev. (1993) 73:229-308.
26. DIEMUNSCH P, GRÉLOT L: Potential of substance P antagonists as antiemetics. Drugs (2000) 60(3):533-546.
27. HÖKFELT T, PERNOW B, WAHREN J: Substance P: a pioneer amongst neuropeptides. J. Int. Med. (2001) 249:27-40.
28. DeVANE CL: Substance P: a new era, a new role. Pharmacotherapy (2001) 21(9):1061-1069.
29. 1 receptor in the brain: pharmacology and putative functions. Eur. J. Pharmacol. (1999) 375:51-60.
30. ANDREWS PL, BHANDARI P: Resinferatoxin, an ultrapotent capsaicin analogue, has anti-emetic properties in the ferret. Neuropharmacology (1993) 32(8):799-806.
31. 1) in the living human brain using positron emission tomography. J. Clin. Psychiatry (2002) 63(Suppl. 11):18-24.
32. ARIUMI H, SAITO R, NAGO S, HYAKUSOKU M, TAKANO Y, KAMIYA H: The role of tachykinin NK-1 receptors in the area postrema of ferrets in emesis. Neurosci. Lett. (2000) 286:123-126.
33. GARDNER CJ, BOUNTRA C, BUNCE K et al.: Anti-emetic activity of neurokinin NK receptor antagonists is mediated centrally in the ferret. Br. J. Pharmacol. (1993):516P.
34. TATTERSALL FD, RYCROFT W, FRANCIS B et al.: Tachykinin NK1 receptor antagonists act centrally to inhibit emesis induced by the chemotherapeutic agent cisplatin in ferrets. Neuropharmacology (1996) 35(8):1121-1129.
35. 1 receptor antagonist MK-0869 (L-754,030) and its water soluble phosphoryl prodrug, L-758,298, inhibit acute and delayed cisplatin-induced emesis in ferrets. Neuropharmacology (2000) 39:652-663.
36. McCREA JB, MAjUMDAR AK, GOLDBERG MR et al.: Effects of the neurokinin 1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone. Clin. Pharmacol. Ther. (2003) 74:17-24.
37. BLUM RA, MAJUMDAR AK, McCREA JB et al.: Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects. Clin. Ther. (2003) 25:1407-1419.
38. MAJUMDAR AK,McCREA JB, PANEBIANCO DL et al.: Effects of aprepitant on cytochrome P450 3A4 activity using midazolam as a probe. Clin. Pharmacol. Ther. (2003) 74(2):150-157.
39. KRIS MG, CUBEDDU LX, GRALLA RJ et al.: Are more antiemetic trials with a placebo necessary? Report of patient data from randomised trials of placebo antiemetics with cisplatin. Cancer (1996) 78(10):2193-2198.
40. COCQUYT V, VAN BELLE S, REINHARDT RR et al.: Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis. Eur. J. Cancer (2001) 37:835-842.
41. VAN BELLE S, LICHINITSER MR, NAVARI RM et al.: Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869: a randomised controlled trial. Cancer (2002) 94(11):3032-3041.
42. CAMPOS D, PEREIRA JR, REINHARDT RR et al.: Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone. J. Clin. Oncol. (2001) 19(6):1759-1767.
43. NAVARI RM, REINHARDT RR, GRALLA RJ et al.: Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. N. Engl. J. Med. (1999) 340(3):190-195.
44. 1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting. Cancer (2003) 97(9 ):2290-2300.
45. POLI-BIGELLI S, RODRIGUES-PEREIRA J, CARIDES AD et al.: Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting: results from a randomised, double-blind, placebo-controlled trial in Latin America. Cancer (2003) 97(12):3090-3098.
46. HESKETH P, GRUNBERG S, GRALLA R et al.: The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomised, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin - the aprepitant protocol 052 study group. J. Clin. Oncol. (2003) 21(22):4112-4119.
47. 1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy. J. Clin. Oncol. (2003) 21(22):4105-4111.
48. 1 antagonist, aprepitant, was effective in maintaining patients' daily life activities in both male and female patients receiving highly emetogenic chemotherapy. Proceedings of the 39th American Society of Clinical Oncology. Chicago, USA (2003):3016.
49. 1 antagonist, aprepitant, is effective in reducing the impact of chemotherapy-induced nausea and vomiting on daily life in both younger and older patients receiving highly emetogenic chemotherapy. Proceedings of the 39th American Society of Clinical Oncology, Chicago, USA (2003):3157.